AstraZeneca Announces Updated Share Capital and Voting Rights

An update from AstraZeneca ( (GB:AZN) ) is now available.

AstraZeneca PLC has announced that as of July 31, 2025, its issued share capital with voting rights consists of 1,550,682,580 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, potentially impacting their interest calculations in the company.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £165.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on GB:AZN Stock

According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.

AstraZeneca’s strong financial performance and positive corporate events are major strengths, contributing to a high overall score. Technical analysis shows bullish momentum but with caution due to overbought signals. Valuation appears high relative to peers, which slightly tempers the overall score.

To see Spark’s full report on GB:AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK. It focuses on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in more than 125 countries and are used by millions of patients worldwide.

Average Trading Volume: 2,321,853

Technical Sentiment Signal: Strong Buy

Current Market Cap: £175.6B

See more insights into AZN stock on TipRanks’ Stock Analysis page.